What is your preferred second-line agent for treatment of metastatic urothelial carcinoma?

Great question, currently only atezolizumab and nivolumab are FDA-approved in this setting. Overall, there are several parameters to take into account (by the way, I suggest a recent review on ASCO "value-based care", which is creating a framework and parameters for the evaluation of cancer drugs ut...